menu
Insights, News, & Events arrow_right News arrow_right

Pfizer and Medivation

22 August 2016 Articles

Pfizer Inc. (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Medivation, a biopharmaceutical company focused on developing and commercializing small molecules for oncology, for $81.50 a share in cash for a total enterprise value of approximately $14 billion. The Boards of Directors of both companies have unanimously approved the merger, which is expected to be immediately accretive to Pfizer’s Adjusted Diluted EPS upon closing, approximately $0.05 accretive in the first full year after close with additional accretion and growth anticipated thereafter. Pfizer does not expect the transaction to impact its current 2016 financial guidance.

Morrow Sodali is acting as information agent for this transaction

Media enquiries

To contact our global experts for comments please get in touch below.

Contact us chevron_right

Contact us

close

Sign up with your email